MN-25 (UR-12) is a drug invented by

Bristol-Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

, that acts as a reasonably selective

agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...

of peripheral

cannabinoid receptor Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system a class of cell membrane receptors in the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cannabinoid recepto ...

s. It has moderate affinity for CB₂ receptors with a ''K''_i of 11 nM, but 22x lower affinity for the psychoactive CB₁ receptors with a ''K''_i of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a ''K''_i of 8 nM at CB₁ and 29 nM at CB₂, which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB₂ (cf.

JWH-018 JWH-018 (1-pentyl-3-(1-naphthoyl)indole, NA-PIMO or AM-678) is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. It produces effects in a ...

JWH-007 JWH-007 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It was first reported in 1994 by a group including the noted cannabinoid chemist John W. Huffman. It was th ...

JWH-081 JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. With a Ki of 1.2nM it is fairly selective for the CB1 subtype, its affinity at this subtype is measured at ap ...

JWH-098 JWH-098 is a synthetic cannabinoid receptor agonist from the naphthoylindole family. It is the indole 2-methyl derivative of a closely related compound JWH-081, but has markedly different affinity for the CB1 and CB2 receptors. While JWH-081 is ...

). Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid,

Org 28611 Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suit ...

, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in

JWH-200 JWH-200 (WIN 55,225) is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity, ''K''i at the CB1 receptor is 42 nM, around the same as that of THC, but its analgesic potency ...

A-796,260 A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3- naphthoyl group found in most indole derived cannabinoids with the 3- tetramethylcy ...

. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.

See also

References

Further reading